NCT06087692 Efficacy of Video-Based Interactive Game Therapy in Interstitial Lung Patients
| NCT ID | NCT06087692 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Istanbul University |
| Condition | Interstitial Lung Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2023-01-01 |
| Primary Completion | 2025-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2023-01-01 with a primary completion date of 2025-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Interstitial lung disease (ILD) is a heterogeneous group of diseases consisting of variable amounts of inflammation and fibrosis and a wide variety of acute and chronic pulmonary disorders affecting both the interstitium and lung parenchyma. The use of gamification elements in order to encourage changes in health behaviors such as physical activity appears as an entertaining option by increasing extrinsic motivation in sedentary individuals or in diseases where physical activity is targeted. The aim of this study is to investigate the effectiveness of Nintendo Wii applied in addition to aerobic exercise in patients with ILD on exercise capacity and peripheral muscle strength, symptoms, activity and participation with objective methods, based on evidence.
Eligibility Criteria
Inclusion Criteria: * Diagnosed with ILD (Interstitial lung disease) by a chest diseases specialist, aged between 40-65 years, and have been under follow-up for at least 6 months according to the current ATS/ERS guidelines. * Clinically stable, with no exacerbations or infections. * Able to walk, with no visual or auditory impairments. * Patients with cognitive abilities sufficient to understand commands. Exclusion Criteria: Orthopedic and neurological problems that could hinder exercise training. * Changes in medical treatment during the study. * Unstable cardiac diseases. * Insufficient cooperation. * Diagnosed visual, auditory, vestibular, or neurological problems that could affect balance.
Contact & Investigator
Aysel Yıldız Özer, Prof.
STUDY DIRECTOR
Marmara University
Frequently Asked Questions
Who can join the NCT06087692 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 65 Years, studying Interstitial Lung Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06087692 currently recruiting?
Yes, NCT06087692 is actively recruiting participants. Contact the research team at mlksrts@hotmail.com for enrollment information.
Where is the NCT06087692 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT06087692 clinical trial?
NCT06087692 is sponsored by Istanbul University. The principal investigator is Aysel Yıldız Özer, Prof. at Marmara University. The trial plans to enroll 30 participants.